Windlas Biotech Reports Record Rs 904 Crore Revenue for FY26

Windlas Biotech Limited announced strong financial results for the fiscal year ending March 31, 2026, with record revenues reaching Rs 904 crores, a 19% increase year-over-year. This achievement extends the company's streak to 13 consecutive quarters of revenue growth.

The company's Contract Development and Manufacturing Organization (CDMO) segment saw its highest revenue to date, generating Rs 664 crores, up 20% from the prior year. Overall, adjusted EBITDA grew 26% year-over-year to Rs 121 crores, while adjusted Profit After Tax (PAT) increased by 31% to Rs 83 crores. Earnings Per Share (EPS) stood at Rs 31.60, an 8% rise. Windlas Biotech maintained a healthy net liquidity of Rs 251 crores and remains net debt-free, supported by Rs 105 crores in cash generated from operations.

Fourth Quarter Performance

In the fourth quarter of FY26, revenue from operations increased by 18% year-over-year to Rs 238 crores. Adjusted EBITDA for the quarter rose 25% YoY to Rs 33 crores, and adjusted PAT experienced a substantial 39% YoY growth to Rs 23 crores.

Growth Drivers and Financial Strength

This consistent performance underscores Windlas Biotech's capacity for profitable expansion. The strong demand for its CDMO services, which form the bulk of its revenue, highlights the effectiveness of its business strategy. The company's debt-free status and robust liquidity position provide significant financial flexibility for future growth initiatives and investments.

A proposed dividend of Rs 6.30 per share for FY26 further signals confidence in its ongoing profitability and commitment to rewarding shareholders.

Strategic Focus and Outlook

Windlas Biotech has prioritized the expansion of its CDMO business, known for its higher margins and stable revenue potential. The company's strategy centers on scalability, durability, and profitability. This sustained growth, now over 13 quarters, reflects strong operational efficiency and market acceptance of its services.

With its record financial performance and solid financial footing, Windlas Biotech is well-positioned for continued expansion. Future efforts are likely to focus on enhancing CDMO capabilities and entering new markets. Its net debt-free position enables strategic acquisitions or increased investment in research and development.

Potential Risks

Despite strong results, Windlas Biotech faces potential risks. These include intensifying competition within the CDMO sector, evolving regulatory landscapes in the pharmaceutical industry, and any general slowdown in global pharmaceutical demand. Reliance on a few key clients in the CDMO segment could also present a challenge.

Industry Context

Windlas Biotech operates in the competitive pharmaceutical contract manufacturing sector. Other notable companies in this field include Syngene International, Gland Pharma, and Laurus Labs. While direct financial comparisons vary based on reporting periods and business mixes, Windlas Biotech's sustained year-over-year growth and expanding EBITDA margins are positive indicators within the industry.

Key Financial Metrics (FY26):

• Revenue: Rs 904 Cr (19% YoY growth)
• CDMO Revenue: Rs 664 Cr (20% YoY growth)
• Adjusted EBITDA: Rs 121 Cr (26% YoY growth)
• Adjusted PAT: Rs 83 Cr (31% YoY growth)
• Net Liquidity: Rs 251 Cr (Net Debt Free)
• Q4FY26 Revenue: Rs 238 Cr (18% YoY growth)
• Proposed Dividend: Rs 6.30 per share

What to Watch Next

Investors will closely monitor Windlas Biotech's upcoming quarterly results, focusing on sustained revenue growth, the expansion of its CDMO services, and the acquisition of new clients. The company's net debt status and cash flow generation will remain key metrics to track.